(Press-News.org) Using gene therapy to produce a mutant human protein with unusually high blood-clotting power, scientists have successfully treated dogs with the bleeding disorder hemophilia, without triggering an unwanted immune response. In addition, the "turbocharged" clotting factor protein eliminated pre-existing antibodies that often weaken conventional treatments for people with hemophilia.
"Our findings may provide a new approach to gene therapy for hemophilia and perhaps other genetic diseases that have similar complications from inhibiting antibodies," said the study leader, Valder R. Arruda, M.D., Ph.D., a hematology researcher at The Children's Hospital of Philadelphia (CHOP).
Arruda and colleagues published their animal study results in the print edition of Blood on March 5.
Hemophilia is an inherited bleeding disorder that famously affected European royal families descended from Queen Victoria. Most commonly occurring in two types, hemophilia A and hemophilia B, the disease impairs the blood's ability to clot, sometimes fatally. When not fatal, severe hemophilia causes painful, often disabling internal bleeding and joint damage.
Doctors treat hemophilia with frequent intravenous infusions of blood clotting proteins called clotting factors, but these treatments are expensive and time-consuming. Moreover, some patients develop inhibiting antibodies that negate the effectiveness of the infusions.
For more than two decades, many research teams, including at CHOP, have investigated gene therapy strategies that deliver DNA sequences carrying genetic code to produce clotting factor in patients. However, this approach has been frustrated by the body's immune response against vectors--the non-disease-causing viruses used to carry the DNA. Those responses, which defeated initial benefits seen in experimental human gene therapy, were dose-dependent: higher amounts of vectors caused more powerful immune responses.
Arruda and colleagues therefore investigated gene therapy that used lower dosages of vector (adeno-associated viral-8 vector, or AAV-8 vector) to produce a more potent clotting factor--a variant protein called FIX-Padua.
Arruda was part of a scientific team in 2009 that discovered FIX-Padua in a young Italian man who had thrombosis, excessive clotting that can dangerously obstruct blood vessels. A mutation produced the mutant clotting factor, called FIX-Padua, named after the patient's city of residence. This was the first mutation in the factor IX gene found to cause thrombosis. All previously discovered FIX mutations lead to hemophilia, the opposite of thrombosis.
FIX-Padua is hyperfunctional--it clots blood 8 to 12 times more strongly than normal, wild-type factor IX. In the current study, the researchers thus needed to strike a balance--to relieve severe hemophilia in dogs, by using a dose strong enough to allow clotting, but not enough to cause thrombosis or stimulate immune reactions. "Our ultimate goal is to translate this approach to humans," said Arruda, "by adapting this variant protein found in one patient to benefit other patients with the opposite disease."
The current study tested the safety of FIX-Padua in three dogs, all with naturally occurring types of hemophilia B very similar to that found in people. Two of the dogs had never been exposed to clotting factor, and had never developed antibodies. The gene therapy injections changed their hemophilia from severe to mild, with no bleeding episodes for up to two years. They did not develop inhibitory antibodies, nor was there evidence of thrombosis.
The third dog, named Wiley, already had inhibitory antibodies before receiving the gene therapy. Wiley also experienced safe and effective treatment of hemophilia, persisting over a sustained period-- three years. The treatment also eradicated the inhibitory antibodies, the first time this occurred in an animal model with pre-existing antibodies.
Another set of preclinical safety studies in mice supported the safety and efficacy of gene therapy using FIX-Padua. Arruda added that larger studies are needed in dogs with pre-existing inhibitors, to confirm these encouraging early results.
In the meantime, at least one clinical trial is making use of FIX-Padua in adult patients with hemophilia B--at the University of North Carolina at Chapel Hill, under Paul Monahan, M.D. Leaders of a separate trial being planned at Spark Therapeutics in Philadelphia, under Katherine A. High, M.D., are contemplating using FIX-Padua as well.
INFORMATION:
The National Institutes of Health (grants HL64190, HL086944) and the National Blood Foundation provided support for this work. Arruda's collaborators were from CHOP and the University of Alabama at Birmingham. In addition to his CHOP position, Arruda is on the faculty of the Perelman School of Medicine at the University of Pennsylvania.
JM Crudele et al,"AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia dogs and mice," Blood, published online Jan. 7, 2015 and in print March 5, 2015. http://doi.org/10.1182/blood-2014-07-588194
Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country. In addition, its unique family-centered care and public service programs have brought the 535-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit http://www.chop.edu.
Despite claims by the Obama administration that the Affordable Care Act will reduce health insurance companies' spending on overhead, thereby channeling a greater share of consumers' premium dollars into actual patient care, insurers' financial filings show the law had no impact on the percentage of insurer expenditures on such things as administration, marketing and profits.
That's the chief finding of a team of researchers, including two prominent physicians on the faculties of the City University of New York's School of Public Health and Harvard Medical School, in ...
Observe whether two people use metaphors in conversation with each other if you want to guess how close they are as friends. Or sharpen your ability to tune into other people's emotional or mental states by observing the metaphors they use. Why is this? Because metaphors can in fact help one to 'mind read,' report Andrea Bowes and Albert Katz of the University of Ontario in Canada in Springer's journal Memory & Cognition.
Metaphor is a type of language that forms part of our daily conversations and communication. In this type of language, the literal or usual meaning ...
EAST LANSING, Mich. - High social status has its privileges -- when it comes to aging -- even in wild animals.
In a first-of-its-kind study involving a wild species, Michigan State University researchers have shown that social and ecological factors affect animal health. The results, published in the current issue of Biology Letters, focused on spotted hyenas in Kenya.
"High-ranking members in hyena clans reproduce more, they live longer and appear to be in better overall health," said Nora Lewin, MSU doctoral student of zoology and co-lead author. "If you want to see ...
WASHINGTON - Two patient groups created by the Affordable Care Act (ACA) - Medicare patients enrolled in federally designated patient-centered medical homes and people under age 26 who are allowed to remain on their parents' health insurance - had slightly fewer emergency department visits than they had before health care reform. However, there was no change in the rate of the most expensive types of emergency visits: those that lead to hospitalization.
One study examined the rate of emergency department visits and hospitalizations for Medicare patients treated by ...
Hurricanes require moisture, the rotation of the earth, and warm ocean temperatures to grow from a mere atmospheric disturbance into a tropical storm. But where do these storm cells originate, and exactly what makes an atmospheric disturbance amp up full throttle?
A new study published in Geophysical Research Letters by Tel Aviv University's Prof. Colin Price and his graduate student Naama Reicher of the Department of Geosciences at TAU's Faculty of Exact Sciences finds most hurricanes over the Atlantic that eventually make landfall in North America actually start as ...
WASHINGTON, March 12, 2015--Borrowing a trick from nature, engineers from the University of California at Berkeley have created an incredibly thin, chameleon-like material that can be made to change color -- on demand -- by simply applying a minute amount of force.
This new material-of-many-colors offers intriguing possibilities for an entirely new class of display technologies, color-shifting camouflage, and sensors that can detect otherwise imperceptible defects in buildings, bridges, and aircraft.
"This is the first time anybody has made a flexible chameleon-like ...
A QUT scientist has helped unravel the way in which plants regulate their levels of vitamin C, the vitamin essential for preventing iron deficiency anaemia and conditions such as scurvy.
Professor Roger Hellens, working with Dr William Laing from New Zealand's Plant and Food Research, has discovered the mechanism plants use to regulate the levels of Vitamin C in each of their cells in response to the environment.
"Understanding these mechanisms may help in plant breeding programmes to produce hardier plant crops and improve human health because iron deficiency anaemia ...
This news release is available in German. Simulations of impressive landscapes and alien creatures have become commonplace, especially in fantasy and science fiction films. But simulations are also appearing in ever more medical and engineering applications. However, the road to a perfect illusion is complex and time-intensive. Nils Thürey, professor at the Technische Universität München and his colleagues have developed a methodology that could accelerate these calculations.
The attack takes place at the climax of the blockbuster "Avatar": Rockets slam ...
"When I interviewed inspectors they are surprisingly open about this. They tell me that they get a box of fish or just some money from fishermen in exchange for being allowed to break the rules that apply to protected areas or catches," says Aksel Sundström.
Many of South Africa's marine fish stocks are overexploited. At the same time, the government actors that are meant to ensure that fishers abide to rules may be a part of the problem.
For example, one anonymous inspector is quoted to say: "A Chinese captain that was arrested last week called someone who arrived ...
CHICAGO (March 12, 2015): A surgical approach in which a surgeon removes less than a lobe of the liver in a patient undergoing an operation for liver cancer is associated with lower mortality and complication rates, according to new study results published online as an "article in press" in the Journal of the American College of Surgeons (JACS). The article will appear in print in the April issue of the Journal.
Historically, the most common surgical method of treatment for liver cancer was a major hepatectomy in which a lobe (hemi-liver) is removed in order to remove ...
